Search research articles
Contact Us
Filters
Showing results (31-40 of 35) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 35 results.
Annals of Neurology
|
September 1, 1992
Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration
Z K Wszolek, R F Pfeiffer, M H Bhatt, et al.
Acta Neuropathologica
|
March 21, 2002
Neuropathology of two members of a German-American kindred (Family C) with late onset parkinsonism
Z K Wszolek, K Gwinn-Hardy, E K Wszolek, et al.
Neurology
|
October 26, 1999
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia
A Brashear, M F Lew, D D Dykstra, et al.
Neurology
|
September 26, 1997
Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia
M F Lew, B T Adornato, D D Duane, et al.
Neurology
|
April 1, 1996
Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease
J T Hutton, W C Koller, J E Ahlskog, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 35) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 35 results.
Annals of Neurology
|
September 1, 1992
Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration
Z K Wszolek, R F Pfeiffer, M H Bhatt, et al.
Acta Neuropathologica
|
March 21, 2002
Neuropathology of two members of a German-American kindred (Family C) with late onset parkinsonism
Z K Wszolek, K Gwinn-Hardy, E K Wszolek, et al.
Neurology
|
October 26, 1999
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia
A Brashear, M F Lew, D D Dykstra, et al.
Neurology
|
September 26, 1997
Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia
M F Lew, B T Adornato, D D Duane, et al.
Neurology
|
April 1, 1996
Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease
J T Hutton, W C Koller, J E Ahlskog, et al.
Page
of 4